Investigators have suspended a Phase I study of NewLink Genetics’ Ebola virus vaccine just weeks after Merck stepped in to license it, citing a safety issue that could delay the pharma giant’s plans to quickly ramp up production.

…read more

Source: Merck hits a hiccup with its new Ebola vaccine


0 No comments